Skip to main content

A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.

Publication ,  Conference
Gray, HJ; Secord, AA; Anderson, ML; DelPriore, G; Tchabo, NE; Berek, JS
Published in: Journal of Clinical Oncology
May 20, 2010

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15_suppl

Start / End Page

TPS171 / TPS171

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gray, H. J., Secord, A. A., Anderson, M. L., DelPriore, G., Tchabo, N. E., & Berek, J. S. (2010). A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. In Journal of Clinical Oncology (Vol. 28, pp. TPS171–TPS171). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.tps171
Gray, H. J., A. A. Secord, M. L. Anderson, G. DelPriore, N. E. Tchabo, and J. S. Berek. “A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.” In Journal of Clinical Oncology, 28:TPS171–TPS171. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.tps171.
Gray HJ, Secord AA, Anderson ML, DelPriore G, Tchabo NE, Berek JS. A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. TPS171–TPS171.
Gray, H. J., et al. “A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. TPS171–TPS171. Crossref, doi:10.1200/jco.2010.28.15_suppl.tps171.
Gray HJ, Secord AA, Anderson ML, DelPriore G, Tchabo NE, Berek JS. A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. TPS171–TPS171.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15_suppl

Start / End Page

TPS171 / TPS171

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences